PCM
NGNE icon

PenderFund Capital Management’s Neurogene NGNE Stock Holding History

PenderFund Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-335
Closed -$6K – 116
2023
Q1 		$6K Buy
+335
New +$3.93K ﹤0.01% 120

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PenderFund Capital Management's NGNE Position: Q2 2023 in Review

PenderFund Capital Management sold out of Neurogene (NGNE) in Q2 2023, closing a stake of 335 shares — an estimated $6K sold.

PenderFund Capital Management first reported a position in NGNE in Q1 2023 and held it in 1 quarter. The position peaked at $6K in Q1 2023. 36 funds tracked by Wall St. Rank hold NGNE as of Q2 2023.

  • PenderFund Capital Management reported no remaining Neurogene position as of Q2 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 335 Neurogene shares in Q2 2023, an estimated $6K.
  • PenderFund Capital Management first reported a position in Neurogene in Q1 2023 and held it in 1 quarter.
  • PenderFund Capital Management's Neurogene position peaked at $6K in Q1 2023.
  • 36 funds tracked by Wall St. Rank held Neurogene as of Q2 2023.

Based on PenderFund Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.